Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

OTC Markets OTCQX - Delayed Quote USD

Sandoz Group AG (SDZXF)

44.94

-3.79

(-7.78%)

At close: February 25 at 12:50:08 PM EST

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in USStrengthens US immunology portfolio and increases access to biologics for patients suffering from chronic inflammatory diseases, such as psoriasis and psoriatic arthritisMeeting a variety of patient needs, Pyzchiva® offers full suite of dosing options and extended stability compared with refer

GlobeNewswire 2 days ago

SDZNY
-1.84%
SDZXF
-7.78%
Francisco Ballester to retire; Peter Stenico appointed President Region International

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of servicePeter Stenico, currently Global Platform Head Biosimilars and Country President Sandoz Austria, concurrently appointed President Region International and a member of the Sandoz Executive Committee Basel, February 3, 2025 – Sandoz, the global leader in generic and biosimilar medicines, announced today that Francisco B

GlobeNewswire 23 days ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilarsLeading in home market Europe, which represents half of total sales; strategically positioning company to become #1 in biosimilars in US, with three US launches expected in 2025Ambitious GLP-1 strategy in place, addressing each opportunity with mix of internal capabilities and external partnershipsIndustry-leading pipeline fo

GlobeNewswire last month

SDZNY
-1.84%
SDZXF
-7.78%
RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement

After Intra-Cellular Therapies (ITCI) announced that it has entered into a settlement agreement with Sandoz (SDZNY) resolving patent litigation related to Intra-Cellular Therapies’ product Caplyta, RBC Capital notes this makes Sandoz the first of the seven ANDA filers to reach a deal. More favorable-than-expected terms for first generic lumateperone settlement bode well for Intra-Cellular’s ability to maintain Caplyta revenue durability, says the firm, which “would be buyers into strength.” RBC

TipRanks last month

ITCI

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know

Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 2 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Here's Why Sandoz Group AG Sponsored ADR (SDZNY) Is a Great 'Buy the Bottom' Stock Now

Sandoz Group AG Sponsored ADR (SDZNY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 2 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for SandozSandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership Basel, November 15, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has g

GlobeNewswire 3 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz reports third-quarter and nine-month 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launchesGenerics growth acceleration driven by EuropeThird-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD)Nine-month net sales of USD 7.6 billion, up 9% in constant currencies (up 8% in USD)Net sales growth guidance increased to high-single digit in constant currencies (

GlobeNewswire 3 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio

MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicineSingle-dose 100 mg vial for intravenous use, approved for metastatic breast cancerLaunch expected to be near-term growth driver in US market Princeton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first generic to its reference medicine to be approved by the US Food and Drug Admi

GlobeNewswire 4 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Introducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian market

— Jubbonti® and Wyost® are first denosumab biosimilars available in Canada, reflecting the Sandoz Purpose of pioneering access for patients — Jubbonti® and Wyost® approved for all indications of respective reference medicines — Sandoz Canada has a leading biosimilars portfolio, with many more in the pipeline BOUCHERVILLE, Quebec, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada, a leader in generics and biosimilars, today announces the launch of two denosumab biosimilars: Jubbonti® and Wyost®. Ju

GlobeNewswire 6 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degenerationFurther enhances leading US ophthalmology portfolio and increases access for patientsExpected to be key biosimilar growth driver in US Basel, August 12, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has approved Enzeevu™ (aflibe

GlobeNewswire 6 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz reports second-quarter sales and half-year 2024 results

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in constant currencies (up 7% in USD)Half-year net sales of USD 5.0 billion, up 7% in constant currencies (up 6% in USD)Half-year core EBITDA margin[2] of 17.5%, a strong 210 basis point improvement versus H2 2023, driven by favorable biosimilars mix; within H1, mar

GlobeNewswire 6 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, starting today, strengthens well-established Sandoz immunology portfolio in Europe, leveraging existing footprintPyzchiva® first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including 130mg vial initiation dose for Crohn’s diseasePyzchiva® to treat adults with pl

GlobeNewswire 6 months ago

SDZNY
-1.84%
SDZXF
-7.78%
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicineFDA granted provisional determination for interchangeability designation for Pyzchiva®Extends Sandoz immunology portfolio and further strengthens biosimilar position Expected to be among first wave of ustekinumab biosimilars to launch in US Basel,

GlobeNewswire 7 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Improving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio

Michel Robidoux Michel Robidoux PrSandoz® Lisdexamfetamine, one of first generic equivalents of Vyvanse*, available on Canadian marketApproved for all indications of reference medicine: Attention Deficit Hyperactivity Disorder and Binge Eating Disorder in adultsPrSandoz® Amoxicillin, PrSandoz® Desvenlafaxine and PrSandoz® Riociguat also joined Sandoz Canada’s generics portfolio this spring BOUCHERVILLE, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada announced today the launch of PrSando

GlobeNewswire 8 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in gener

GlobeNewswire 9 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz reports first quarter 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)Biosimilar business growing 21% in constant currencies All regions contributing to growthAcquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the f

GlobeNewswire 9 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

All proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmedMathai Mammen, Graeme Pitkethly and Michael Rechsteiner elected as new Board membersDividend of CHF 0.45 per registered dividend-paying share approved, representing 24% of core net income Basel, April 30, 2024 – Sandoz (SIX: SDZ; OTCQX: SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its

GlobeNewswire 9 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on May 31, 2025 or earlier under certain circumstancesJubbonti® and Wyost® are first and only FDA-approved biosimilars to and interchangeable with Prolia*® and Xgeva*®Anticipated launch further strengthens Sandoz biosimilar portfolio and advances growth strategy

GlobeNewswire 9 months ago

SDZNY
-1.84%
SDZXF
-7.78%
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and qualitySandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolio Basel, April 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today an

GlobeNewswire 10 months ago

SDZNY
-1.84%
SDZXF
-7.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sandoz Group AG (SDZXF)

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Francisco Ballester to retire; Peter Stenico appointed President Region International

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement

Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know

Here's Why Sandoz Group AG Sponsored ADR (SDZNY) Is a Great 'Buy the Bottom' Stock Now

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio

Introducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian market

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Improving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Sandoz reports first quarter 2024 sales

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering